News | April 07, 2024
Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
The agreement sets terms under which POC will manufacture the product or receive royalties
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Cipla shall now have exclusive rights for the development and commercialisation of Pulmazole in all countries except the United States of America
Collaboration provides AstraZeneca with exclusive rights to Omniose’s proprietary bioconjugation platform to explore potential vaccines for a broad range of bacterial pathogens
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Subscribe To Our Newsletter & Stay Updated
